ELAC2

From Wikipedia, the free encyclopedia

ElaC homolog 2 (E. coli)

Identifiers

ELAC2; HPC2; ELC2; FLJ10530; FLJ36693; FLJ42848

External IDs

OMIM: 605367 MGI: 1890496 HomoloGene: 6403

Gene ontology
Molecular Function:	• endonuclease activity • zinc ion binding • hydrolase activity • metal ion binding
Cellular Component:	• nucleus
Biological Process:	• tRNA processing

RNA expression pattern

More reference expression data

Orthologs

Human

Mouse

Refseq

NM_018127 (mRNA)
NP_060597 (protein)

NM_023479 (mRNA)
NP_075968 (protein)

Location

Chr 17: 12.84 - 12.86 Mb

Chr 11: 64.8 - 64.82 Mb

Pubmed search

[1]

[2]

ElaC homolog 2 (E. coli), also known as ELAC2, is a human gene.^[1]

[edit] References

^ Entrez Gene: ELAC2 elaC homolog 2 (E. coli).

[edit] Further reading

Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery.". Genome Res. 6 (9): 791–806. PMID 8889548.
Satijn DP, Gunster MJ, van der Vlag J, et al. (1997). "RING1 is associated with the polycomb group protein complex and acts as a transcriptional repressor.". Mol. Cell. Biol. 17 (7): 4105–13. PMID 9199346.
Sewalt RG, Gunster MJ, van der Vlag J, et al. (1999). "C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins.". Mol. Cell. Biol. 19 (1): 777–87. PMID 9858600.
Rebbeck TR, Walker AH, Zeigler-Johnson C, et al. (2000). "Association of HPC2/ELAC2 genotypes and prostate cancer.". Am. J. Hum. Genet. 67 (4): 1014–9. PMID 10986046.
Tavtigian SV, Simard J, Teng DH, et al. (2001). "A candidate prostate cancer susceptibility gene at chromosome 17p.". Nat. Genet. 27 (2): 172–80. doi:10.1038/84808. PMID 11175785.
Xu J, Zheng SL, Carpten JD, et al. (2001). "Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.". Am. J. Hum. Genet. 68 (4): 901–11. PMID 11254448.
Rökman A, Ikonen T, Mononen N, et al. (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.". Cancer Res. 61 (16): 6038–41. PMID 11507049.
Wang L, McDonnell SK, Elkins DA, et al. (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer.". Cancer Res. 61 (17): 6494–9. PMID 11522646.
Shea PR, Ferrell RE, Patrick AL, et al. (2002). "ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago.". Hum. Genet. 111 (4-5): 398–400. doi:10.1007/s00439-002-0816-1. PMID 12384782.
Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
Camp NJ, Tavtigian SV (2003). "Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer.". Am. J. Hum. Genet. 71 (6): 1475–8. PMID 12515253.
Fujiwara H, Emi M, Nagai H, et al. (2003). "Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.". J. Hum. Genet. 47 (12): 641–8. doi:10.1007/s100380200099. PMID 12522685.
Korver W, Guevara C, Chen Y, et al. (2003). "The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.". Int. J. Cancer 104 (3): 283–8. doi:10.1002/ijc.10945. PMID 12569551.
Shi Y, Sawada J, Sui G, et al. (2003). "Coordinated histone modifications mediated by a CtBP co-repressor complex.". Nature 422 (6933): 735–8. doi:10.1038/nature01550. PMID 12700765.
Takaku H, Minagawa A, Takagi M, Nashimoto M (2003). "A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease.". Nucleic Acids Res. 31 (9): 2272–8. PMID 12711671.
Severi G, Giles GG, Southey MC, et al. (2003). "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.". J. Natl. Cancer Inst. 95 (11): 818–24. PMID 12783937.
Takahashi H, Lu W, Watanabe M, et al. (2003). "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.". Int. J. Cancer 107 (2): 224–8. doi:10.1002/ijc.11347. PMID 12949798.
Stanford JL, Sabacan LP, Noonan EA, et al. (2003). "Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.". Cancer Epidemiol. Biomarkers Prev. 12 (9): 876–81. PMID 14504198.
Adler D, Kanji N, Trpkov K, et al. (2004). "HPC2/ELAC2 gene variants associated with incident prostate cancer.". J. Hum. Genet. 48 (12): 634–8. doi:10.1007/s10038-003-0091-6. PMID 14625808.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.